Parkinsonism & Related Disorders
Volume 16, Issue 2 , Pages 142-145 , February 2010

Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders

  • Radu Constantinescu

      Affiliations

    • Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 31 3421000.
    • ,
  • Lars Rosengren

      Affiliations

    • Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
    • ,
  • Bo Johnels

      Affiliations

    • Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
    • ,
  • Henrik Zetterberg

      Affiliations

    • Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, 431 80 Mölndal, Sweden
    • ,
  • Bjorn Holmberg

      Affiliations

    • Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden

Received 16 November 2008 ,Revised 23 June 2009 ,Accepted 15 July 2009.

References 

  1. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003 Oct 10;987(1):25–31
  2. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord. 1998 Jan;13(1):70–77
  3. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging. 2007 May;28(5):742–747
  4. Tullberg M, Rosengren L, Blomsterwall E, Karlsson JE, Wikkelso C. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology. 1998 Apr;50(4):1122–1127
  5. Abdo WF, De Jong D, Hendriks JC, Horstink MW, Kremer BP, Bloem BR, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord. 2004 May;19(5):571–579
  6. Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res. 1998 Dec;8(6):359–362
  7. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996 Jul;47(1):1–9
  8. Lang AE, Riley DE, Bergeron C. Cortico-basal ganglionic degeneration. In:  Calne D editors. Neurodegenerative diseases. Philadephia: WB Saunders; 1994;p. 877–894
  9. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996 Nov;67(5):2013–2018
  10. Rosengren LE, W C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods. 1994;1994(51):197–204
  11. Brettschneider J, Petzold A, Sussmuth SD, Landwehrmeyer GB, Ludolph AC, Kassubek J, et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord. 2006 Dec;21(12):2224–2227
  12. Abdo WF, van de Warrenburg BP, Kremer HP, Bloem BR, Verbeek MM. CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy. Parkinsonism Relat Disord. 2007 Dec;13(8):480–482

☆ The review of this paper was entirely handled by an Associate Editor, Vincenzo Bonifati.

PII: S1353-8020(09)00196-5

doi: 10.1016/j.parkreldis.2009.07.007

Parkinsonism & Related Disorders
Volume 16, Issue 2 , Pages 142-145 , February 2010

Article Tools

* Image Usage & Resolution